Full Papers
Burden of illness in fibromyalgia patients with comorbid depression
L. Bateman1, P. Sarzi-Puttini2, C.L. Burbridge3, J.W. Landen4, E.T. Masters5, P. Bhadra Brown6, J.M. Scavone7, B. Emir8, R.S. Vissing9, A.G. Clair10, L.R. Pauer11
- Bateman Horne Center, Salt Lake City, UT, USA.
- Azienda Ospedaliera Polo Universitario L. Sacco, Milano, Italy.
- Clinical Outcomes Solutions, Folkestone, Kent, UK.
- Pfizer Inc, Groton, CT, USA.
- Pfizer Inc, New York, NY, USA.
- Pfizer Inc, New York, NY, USA.
- Pfizer Inc, Groton, CT, USA.
- Pfizer Inc, Groton, CT, USA.
- Pfizer Inc, Louisville, KY, USA.
- Pfizer Inc, New York, NY, USA.
- Pfizer Inc, Groton, CT, USA. lynne.pauer@pfizer.com
CER8898
2016 Vol.34, N°2 ,Suppl.96
PI 0106, PF 0113
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 27057659 [PubMed]
Received: 25/08/2015
Accepted : 08/02/2016
In Press: 10/03/2016
Published: 06/05/2016
Abstract
OBJECTIVES:
To assess the burden of fibromyalgia (FM) in patients with FM taking antidepressant medication for comorbid depression.
METHODS:
Symptom burden, impact on work and activity, and healthcare resource utilisation (HCRU) was examined at randomisation in patients enrolled in a clinical trial. Symptom burden was estimated based on self-reported health status measures. The Work Productivity and Activity Impairment: Specific Health Problem scale adapted to FM and a separate HCRU questionnaire were completed. The relationship between FM severity and burden was evaluated.
RESULTS:
The total population analysed comprised 193 patients; 71 (36.8%) had moderate FM and 119 (61.7%) severe FM. Patients had moderate pain, severe impairment in functioning due to FM, sleep disruption, mild anxiety, and mild depression. In the 7 days preceding randomisation, an average of 58.0% overall work impairment was reported, with 15.2% of working hours missed and 54.0% productivity while at work. In the 3 months preceding randomisation, on average, 5.0 visits per patient were made to healthcare professionals. Physical treatments were used by 34.7% and supplements by 31.6% of patients. Prescription and non-prescription medications, as well as professional services providing help with activities of daily living (ADL) that are impacted by FM, were used by >75% of patients. In addition, 50.4 hours of unpaid help was provided for ADL assistance. Total out-of-pocket expenditures were US$307.1, €410.4, or C$211.3, depending on location. FM burden worsened with increasing FM severity.
CONCLUSIONS:
This study demonstrates the significant burden of FM in patients with comorbid depression treated with an antidepressant.